CHMP has recommended that the European Commission approve Gilead Sciences' lenacapavir. The drug is intended to treat HIV-1 infection in combination with other antiretroviral drugs in multidrug-resistant adults for whom a suppressive antiviral regimen cannot otherwise be established. The European Commission will make its final decision during this year.